Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism.

Abstract:

:In this study, the abilities of constitutive and conditional forms of the three Raf kinases to abrogate the cytokine dependency of FDC-P1 cells were examined. The constitutively active forms (delta) of all three Raf kinases were fused to the hormone-binding domain of the estrogen receptor (ER), rendering their activities conditionally dependent upon exogenous beta-estradiol. The vast majority of deltaRaf:ER-infected FDC-P1 cells remained cytokine-dependent; however, cells were obtained at low frequency in which expression of deltaRaf:ER abrogated cytokine dependency. Isoform specific differences between the Raf kinases were observed as cytokine-independent cells were obtained more frequently from deltaA-Raf:ER than either deltaRaf-1:ER or deltaB-Raf:ER infected cells. To determine whether the regulatory phosphorylation sites in the Raf proteins were necessary for abrogation of cytokine dependency, they were changed by site-directed mutagenesis. Substitution with phenylalanine eliminated the transforming ability of the deltaB-Raf:ER and deltaRaf-1:ER kinases. However, a similar substitution in A-Raf did not extinguish its transforming activity. The activated Raf proteins induced essential downstream MEK1 activity as treatment with the MEK1 inhibitor, PD98059, suppressed Raf-mediated growth. Activated MAP kinases (ERK1 and ERK2) were detected in deltaRaf:ER-transformed cells, and their presence was dependent upon a functional MEK1 protein. The cytokine-independent phenotype required the continued activity of the deltaRaf:ER proteins as removal of beta-estradiol caused the cells to stop growing and undergo apoptosis. The Raf-responsive cells were found to express autocrine growth factors, which promoted their growth. Constitutive activation of the Raf-1 oncogene resulted in malignant transformation as cytokine-independent FDC-P1 cells infected with a retrovirus encoding an activated Raf-1 protein formed tumors upon injection of immunocompromised mice. In summary, Raf kinases can abrogate cytokine dependency, prevent apoptosis and induce the tumorigenicity of a certain subpopulation of FDC-P1 cells by a MEK1-dependent mechanism.

journal_name

Leukemia

journal_title

Leukemia

authors

Hoyle PE,Moye PW,Steelman LS,Blalock WL,Franklin RA,Pearce M,Cherwinski H,Bosch E,McMahon M,McCubrey JA

doi

10.1038/sj.leu.2401720

subject

Has Abstract

pub_date

2000-04-01 00:00:00

pages

642-56

issue

4

eissn

0887-6924

issn

1476-5551

journal_volume

14

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.

    abstract::The R98S mutation in ribosomal protein L10 (RPL10 R98S) affects 8% of pediatric T-cell acute lymphoblastic leukemia (T-ALL) cases, and was previously described to impair cellular proliferation. The current study reveals that RPL10 R98S cells accumulate reactive oxygen species which promotes mitochondrial dysfunction a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0176-z

    authors: Kampen KR,Sulima SO,Verbelen B,Girardi T,Vereecke S,Rinaldi G,Verbeeck J,Op de Beeck J,Uyttebroeck A,Meijerink JPP,Moorman AV,Harrison CJ,Spincemaille P,Cools J,Cassiman D,Fendt SM,Vermeersch P,De Keersmaecker K

    更新日期:2019-02-01 00:00:00

  • Hematopoietic growth factors in acute leukemia.

    abstract::The hematopoietic growth factors are glycoproteins that can be produced by recombinant DNA technology. They have many potential clinical uses in acute leukemia; several areas have been explored extensively and much data are available from clinical trials. Other areas are of potential interest, but have a paucity of cl...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2400592

    authors: Rowe JM,Liesveld JL

    更新日期:1997-03-01 00:00:00

  • Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers.

    abstract::Sequential analysis of chimerism after allogeneic blood stem cell transplantation (BSCT) has been shown to be predictive for graft failure and relapse. We have explored the impact of a novel approach for the quantitative determination of chimerism using a commercial PCR assay with multiplex amplification of nine STR-l...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401953

    authors: Thiede C,Bornhäuser M,Oelschlägel U,Brendel C,Leo R,Daxberger H,Mohr B,Florek M,Kroschinsky F,Geissler G,Naumann R,Ritter M,Prange-Krex G,Lion T,Neubauer A,Ehninger G

    更新日期:2001-02-01 00:00:00

  • Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms.

    abstract::Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized by chronic proliferation of hematopoietic progenitors. We studied the telomere length (TL) of 335 MPN patients and 93 gender- and age-matched controls using a quantitative PCR method (relative TL calculated as the ratio of the amount of t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.319

    authors: Bernard L,Belisle C,Mollica L,Provost S,Roy DC,Gilliland DG,Levine RL,Busque L

    更新日期:2009-02-01 00:00:00

  • The retinoic acid alpha receptor gene is frequently disrupted in its 5' part in Chinese patients with acute promyelocytic leukemia.

    abstract::The t(15;17)(q22;q11-q21) translocation, a hallmark for acute promyelocytic leukemia (APL), has recently been shown to disrupt the retinoic acid-alpha receptor (RARA) gene localized on band 17q21. Leukemic cell DNAs from 16 Chinese patients with APL were analysed by Southern blot hybridization with probes covering the...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Chen Z,Chen SJ,Tong JH,Zhu YJ,Huang ME,Wang WC,Wu Y,Sun GL,Wang ZY,Larsen CJ

    更新日期:1991-04-01 00:00:00

  • The biological consequences of excess GM-CSF levels in transgenic mice also lacking high-affinity receptors for GM-CSF.

    abstract::GM-CSF transgenic mice were crossed with mice with homozygous inactivation of the gene encoding the common beta chain (beta c) of the GM-CSF receptor to produce mice with constitutively elevated GM-CSF levels but no high-affinity GM-CSF receptors. GM-CSF transgenic beta c -/- mice had exceptionally elevated serum GM-C...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400926

    authors: Metcalf D,Mifsud S,Di Rago L,Robb L,Nicola NA,Alexander W

    更新日期:1998-03-01 00:00:00

  • The diagnositc significance of Myf-3 hypermethylation in malignant lymphoproliferative disorders.

    abstract::Deregulated methylation of cytosine in DNA is a frequent finding in malignancy that is reflected by general genomic hypomethylation and regional hypermethylation that includes the myogenic gene Myf-3. In this study of 198 DNA samples from 186 patients with a wide range of lymphoproliferative disorders (LPD), the methy...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402080

    authors: Taylor JM,Kay PH,Spagnolo DV

    更新日期:2001-04-01 00:00:00

  • Haplotype study of microsatellites flanking the t(15;17) breakpoint in acute promyelocytic leukemia patients from North Portugal.

    abstract::A higher frequency of acute promyelocytic leukemia (APL) has been noted in countries of Southern Europe and among 'Latino' patients of the United States with acute myeloid leukemia (AML). In order to discover whether there is any genetic predisposition to the disease, we analyzed microsatellites flanking PML and RARal...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402525

    authors: Martins S,Trigo F,Azevedo L,Silva MJ,Guimaraes JE,Amorim A

    更新日期:2002-07-01 00:00:00

  • Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.

    abstract::Outcomes for patients with multiple myeloma (MM) have improved in recent years owing to use of novel agents and high-dose therapy followed by autologous stem cell transplant (ASCT). We analyzed the outcomes of 511 consecutive patients treated with novel therapies at our institution between 2006 and 2014 to determine t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.147

    authors: Majithia N,Rajkumar SV,Lacy MQ,Buadi FK,Dispenzieri A,Gertz MA,Hayman SR,Dingli D,Kapoor P,Hwa L,Lust JA,Russell SJ,Go RS,Kyle RA,Kumar SK

    更新日期:2016-11-01 00:00:00

  • Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.

    abstract::Drug resistance is a growing area of concern. It has been shown that a small, residual pool of leukemic CD34+ progenitor cells can survive in the marrow microenvironment of chronic myeloid leukemia (CML) patients after years of kinase inhibitor treatment. Bone marrow (BM) stroma has been implicated in the long-term su...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.360

    authors: Weisberg E,Azab AK,Manley PW,Kung AL,Christie AL,Bronson R,Ghobrial IM,Griffin JD

    更新日期:2012-05-01 00:00:00

  • Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

    abstract::This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide-dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ⩾65 years or transplant ineligible. Patients received wKCyd for up to nine 28-day cycles, followed by maintenance with c...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2017.327

    authors: Bringhen S,D'Agostino M,De Paoli L,Montefusco V,Liberati AM,Galieni P,Grammatico S,Muccio VE,Esma F,De Angelis C,Musto P,Ballanti S,Offidani M,Petrucci MT,Gaidano G,Corradini P,Palumbo A,Sonneveld P,Boccadoro M

    更新日期:2018-04-01 00:00:00

  • BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.

    abstract::Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling that responds to treatment with the JAK1 and 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary acu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.260

    authors: Saenz DT,Fiskus W,Manshouri T,Rajapakshe K,Krieger S,Sun B,Mill CP,DiNardo C,Pemmaraju N,Kadia T,Parmar S,Sharma S,Coarfa C,Qiu P,Verstovsek S,Bhalla KN

    更新日期:2017-03-01 00:00:00

  • Human bone marrow cytogenetics: growth factors stimulate metaphases for specific lineages.

    abstract::Fresh and/or frozen bone marrow cells from five healthy individuals and seven patients with myeloid leukemia were studied using growth factors and a cytogenetic technique which allows simultaneous analysis of karotype and cell lineage. Cell lineages were identified using monoclonal antibodies in an alkaline phosphatas...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Keinänen M,Bloomfield CD,Machnicki J,Griffin JD,de la Chapelle A

    更新日期:1989-06-01 00:00:00

  • A prospective, randomized, double-blind study, comparing unirradiated to irradiated white blood cell transfusions in acute leukemia patients.

    abstract::A prospective, randomized double-blind study comparing the effects of irradiated and unirradiated white blood cells was conducted in 108 acute leukemia patients with life-threatening infections, refractory to antibiotics. The study demonstrated no significant improvement in 30-day survival or overall survival. Transfu...

    journal_title:Leukemia

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/leu.2012.301

    authors: Freireich EJ,Lichtiger B,Mattiuzzi G,Martinez F,Reddy V,Kyle Wathen J

    更新日期:2013-04-01 00:00:00

  • Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients.

    abstract::The serine/threonine kinase Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), is known to play an important role in antiapoptotic signaling and has been implicated in the aggressiveness of a number of different human cancers including acute myeloid leukemia (AML). The progression of myelodysplastic s...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404057

    authors: Nyåkern M,Tazzari PL,Finelli C,Bosi C,Follo MY,Grafone T,Piccaluga PP,Martinelli G,Cocco L,Martelli AM

    更新日期:2006-02-01 00:00:00

  • Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.

    abstract::In patients with hematologic malignancy, invasive aspergillosis continues to be associated with high mortality even when treated with conventional antifungal therapy. To investigate novel antifungal agents, we compared 53 patients who received posaconazole salvage therapy to 52 contemporary control patients who receiv...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/sj.leu.2405065

    authors: Raad II,Hanna HA,Boktour M,Jiang Y,Torres HA,Afif C,Kontoyiannis DP,Hachem RY

    更新日期:2008-03-01 00:00:00

  • BCL2 mutations in diffuse large B-cell lymphoma.

    abstract::BCL2 is deregulated in diffuse large B-cell lymphoma (DLBCL) by the t(14;18) translocation, gene amplification and/or nuclear factor-κB signaling. RNA-seq data have recently shown that BCL2 is the most highly mutated gene in germinal center B-cell (GCB) DLBCL. We have sequenced BCL2 in 298 primary DLBCL biopsies, 131 ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.378

    authors: Schuetz JM,Johnson NA,Morin RD,Scott DW,Tan K,Ben-Nierah S,Boyle M,Slack GW,Marra MA,Connors JM,Brooks-Wilson AR,Gascoyne RD

    更新日期:2012-06-01 00:00:00

  • Expression of the LH2 gene in chronic myeloid leukaemia cells.

    abstract::The LH2 gene encodes a putative transcription factor containing two N-terminal LIM and one C-terminal HOX domains. The LH2 locus was mapped to 9q33-34.1, centromeric to the ABL gene. In a recent report, it was suggested that high levels of LH2 expression are consistently observed in chronic myeloid leukemia (CML) pati...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Al-Jehani F,Hochhaus A,Spencer A,Goldman JM,Melo JV

    更新日期:1996-07-01 00:00:00

  • Myeloid differentiation antigens identify leukemic cell subpopulations with different cell cycle characteristics.

    abstract::In order to assess the proliferative capacity of leukemic subpopulations and to know whether it can be related to the stage of maturation, the expression of two surface antigens identifying distinct steps of leukocyte differentiation (CD15 and CD34) was studied by flow cytometry in correlation with DNA content in 16 c...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Campos L,Ffrench M,Guyotat D

    更新日期:1990-01-01 00:00:00

  • How to manage essential thrombocythemia.

    abstract::I use the hematological, morphological and molecular criteria recently established by the World Health Organization to diagnose essential thrombocytemia. In these patients, major causes of morbidity and mortality are represented by thrombosis and bleeding, whereas progression to myelofibrosis and transformation to acu...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2011.306

    authors: Finazzi G

    更新日期:2012-05-01 00:00:00

  • Monoclonal antibodies specific for P-glycoprotein.

    abstract::Multidrug resistance (MDR) is one of the major obstacles to successful cancer chemotherapy. Since P-glycoprotein (P-gp) encoded by the MDR-1 gene plays a key role in MDR, many P-gp-specific monoclonal antibodies (MAbs) have been generated for characterization and analysis of P-gp. Among those antibodies, MRK16 has bee...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2400658

    authors: Okochi E,Iwahashi T,Tsuruo T

    更新日期:1997-07-01 00:00:00

  • Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.

    abstract::Chronic lymphocytic leukemia (CLL) cells could be undetectable by flow cytometry or polymerase chain reaction after sequential treatment with fludarabine and Campath-1H. Concern has been raised regarding the ability to mobilize sufficient peripheral blood progenitor cells (PBPCs) for autografting after purine analogue...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403190

    authors: Montillo M,Tedeschi A,Rossi V,Cairoli R,Pungolino E,Intropido L,Cafro AM,D'Avanzo G,Farioli R,Brando B,Scarpati B,Veronese S,Morra E

    更新日期:2004-01-01 00:00:00

  • Translocation t(14;18) and gain of chromosome 18/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin's lymphomas.

    abstract::Gain of chromosome 18q and translocation t(14;18) are] frequently found in B-cell non-Hodgkin's lymphomas (B-NHL). Increased BCL2 transcription and BCL2 protein expression have been suggested to be the result of the gain. We utilized FISH, PCR and array CGH to study BCL2 and chromosome 18 copy number changes and rearr...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403954

    authors: Galteland E,Sivertsen EA,Svendsrud DH,Smedshammer L,Kresse SH,Meza-Zepeda LA,Myklebost O,Suo Z,Mu D,Deangelis PM,Stokke T

    更新日期:2005-12-01 00:00:00

  • Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

    abstract::After accounting for misdiagnosis and treatment effect, allele-specific (AS)-PCR detects the JAK2V617F mutation in >95% of polycythemia vera (PV) patients. Using database inquiry, we identified 6 of a total 220 cases with PV that were JAK2V617F-negative (prevalence=3%). Of these, five cases ( approximately 80%) were f...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404810

    authors: Pardanani A,Lasho TL,Finke C,Hanson CA,Tefferi A

    更新日期:2007-09-01 00:00:00

  • Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

    abstract::The 2001 World Health Organization (WHO) treatise on the classification of hematopoietic tumors lists chronic myeloproliferative diseases (CMPDs) as a subdivision of myeloid neoplasms that includes the four classic myeloproliferative disorders (MPDs)-chronic myelogenous leukemia, polycythemia vera (PV), essential thro...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2404955

    authors: Tefferi A,Vardiman JW

    更新日期:2008-01-01 00:00:00

  • Insulin-like growth factor 1 is a direct HOXA9 target important for hematopoietic transformation.

    abstract::HOX homeobox proteins are key oncogenic drivers in hematopoietic malignancies. Here we demonstrate that HOXA1, HOXA6 and predominantly HOXA9 are able to induce the production of insulin-like growth factor 1 (Igf1). In chromatin immunoprecipitations, HOXA9 bound directly to the putative promoter and a DNase-hypersensit...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.287

    authors: Steger J,Füller E,Garcia-Cuellar MP,Hetzner K,Slany RK

    更新日期:2015-04-01 00:00:00

  • Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

    abstract::This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in lenalidomide-refractory and proteasome inhibitor-exposed relapsed or relapsed and refractory multiple myeloma (RRMM). In 21-day cycles, patients received pomalidomide (1-4...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.173

    authors: Richardson PG,Hofmeister CC,Raje NS,Siegel DS,Lonial S,Laubach J,Efebera YA,Vesole DH,Nooka AK,Rosenblatt J,Doss D,Zaki MH,Bensmaine A,Herring J,Li Y,Watkins L,Chen MS,Anderson KC

    更新日期:2017-12-01 00:00:00

  • Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms.

    abstract::The unbalanced translocation, der(1;7)(q10;p10), is one of the characteristic cytogenetic abnormalities found in myelodysplastic syndromes (MDS) and other myeloid neoplasms. Although described frequently with very poor clinical outcome and possible relationship with monosomy 7 or 7q- (-7/7q-), this recurrent cytogenet...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404619

    authors: Sanada M,Uike N,Ohyashiki K,Ozawa K,Lili W,Hangaishi A,Kanda Y,Chiba S,Kurokawa M,Omine M,Mitani K,Ogawa S

    更新日期:2007-05-01 00:00:00

  • Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

    abstract::In diffuse large B-cell lymphoma (DLBCL), the clinical and biological significance of concordant and discordant bone marrow (BM) involvement have not been well investigated. We evaluated 712 de novo DLBCL patients with front-line rituximab-containing treatment, including 263 patients with positive and 449 with negativ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.222

    authors: Yao Z,Deng L,Xu-Monette ZY,Manyam GC,Jain P,Tzankov A,Visco C,Bhagat G,Wang J,Dybkaer K,Tam W,Hsi ED,van Krieken JH,Ponzoni M,Ferreri AJM,Møller MB,Winter JN,Piris MA,Fayad L,Liu Y,Song Y,Orlowski RZ,Kantarjia

    更新日期:2018-02-01 00:00:00

  • The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation.

    abstract::Hematopoietic stem cell transplantation is becoming an increasingly important approach to treatment of different malignant and non-malignant disorders. There is thus growing demand for diagnostic assays permitting the surveillance of donor/recipient chimerism posttransplant. Current techniques are heterogeneous, rende...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.66

    authors: Lion T,Watzinger F,Preuner S,Kreyenberg H,Tilanus M,de Weger R,van Loon J,de Vries L,Cavé H,Acquaviva C,Lawler M,Crampe M,Serra A,Saglio B,Colnaghi F,Biondi A,van Dongen JJ,van der Burg M,Gonzalez M,Alcoceba M,Bar

    更新日期:2012-08-01 00:00:00